Zymewire, the leading sales intelligence management system for service providers in the life sciences industry, today released its 2025 Annual Biopharma Recap Report. Building on the executive earnings call analysis introduced in the midyear edition, this report expands its source base to include exclusive industry podcast content, making it the first Zymewire publication to incorporate qualitative intelligence unavailable through any other channel. The result is a full-year view of global biopharma funding, drug pipeline activity, planned clinical trials, and study initiations and closeouts, contextualized by the strategic thinking of senior industry leaders.

Across 2025, biopharma companies globally raised approximately $124.12 billion in operating capital. The report captures a year marked by meaningful regional divergence, shifting investment patterns, and a clinical pipeline that tells a more nuanced story than headline funding figures alone.

Regionally, full-year 2025 funding trends reflected distinct trajectories:

• North American biopharma companies raised approximately $85.57 billion, with activity heavily concentrated in the second half of the year.
• European funding remained relatively stable throughout, closing the year at approximately $24.89 billion.
• APAC funding totaled approximately $13.66 billion, characterized by significant quarter-to-quarter volatility.

"The 2025 Biopharma Recap represents a meaningful step forward in what sales intelligence can actually deliver," said Pete Bastedo, CEO of Zymewire. "General-purpose AI tools can surface data, but they cannot replicate the depth that comes from years of vertical focus on biopharma combined with exclusive access to how senior leaders in this industry are genuinely thinking. By pairing our proprietary data with insights from earnings calls and content you will not find anywhere else, we are giving commercial teams at CROs and CDMOs the kind of contextualized intelligence you can work with to drive commercial strategy."

New Biotech Formation Continues to Moderate

The 2025 Annual Biopharma Recap identified 274 newly formed biotech companies over the course of the year, continuing a gradual decline from 296 in 2024 and 321 in 2023. Despite ongoing funding pressures on early-stage companies, the continued emergence of new entrants signals sustained innovation activity and a pipeline of early-stage relationships for proactive service providers to cultivate.

APAC Emerges as a Force in Early-Stage Clinical Activity

One of the report's defining findings is APAC's position in Phase 1 study initiations, where the region outpaced North America in 2025. China's continued investment in early-stage clinical infrastructure is a primary driver, a trend with direct implications for CROs and CDMOs assessing where first-in-human capacity demand is building globally.

Zymewire's 2025 Annual Biopharma Recap offers actionable intelligence for service providers, with new data and insights on the following:

• Exclusive qualitative analysis drawn from biopharma earnings calls and proprietary industry channels.
• Global biopharma funding regionally and quarterly, with year-over-year comparisons.
• Cumulative funding by company size, therapeutic area, and pipeline maturity.
• Active drug pipeline breakdown by development phase, modality, and route of administration across North America, Europe, and APAC.
• Planned clinical trials by phase, region, and therapeutic area.
• Global study initiations and closeouts by phase and region.
• Newly identified biotech companies with a year-over-year comparison.

The full report is available now. To access the complete report and explore more data insights, download it here.